Sanofi, AstraZeneca in major drug-sharing deal
Advertisement
French pharmaceutical company Sanofi and Britain's AstraZeneca said they have agreed to share freely 210,000 proprietary chemical compounds as they pursue the development of new drugs.
Sanofi hailed the move as "a new open innovation model between two major pharmaceutical groups" who normally are major competitors in a multibillion business creating the building blocks of treatments for diseases.
The novel arrangement of exchanging compounds from their separate compound libraries will "allow both to sift a much larger and more diversified number of small molecules likely to become future medicines," Sanofi added in a statement.
Sanofi hailed the move as "a new open innovation model between two major pharmaceutical groups" who normally are major competitors in a multibillion business creating the building blocks of treatments for diseases.
The novel arrangement of exchanging compounds from their separate compound libraries will "allow both to sift a much larger and more diversified number of small molecules likely to become future medicines," Sanofi added in a statement.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.